HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

POSSIBILITIES OF CORRECTING METABOLIC DISORDERS IN CHILDREN WITH CHRONIC HEART FAILURE

Download full text PDF
Issue: 
1
Year: 
2016

I. Samokhina (1), Candidate of Medical Sciences; Professor E. Basargina (1), MD; G. Semenova (1), Biol.D; O. Kurbatova (1); L. Maksimova (2), Candidate of Medical Sciences; N. Fedorova (1); L. Miroshkina (1), Candidate of Medical Sciences; T. Izmailova (1), Candidate of Medical Sciences; Professor S. Petrichuk (1), Biol.D 1 -Children’s Health Research Center, Moscow 2 -Research Institute of Cytochemistry and Molecular Pharmacology, Moscow

In children with heart diseases accompanied by chronic heart disease (CHD) the activity of major energy metabolic enzymes (succinate dehydrogenase and glycerol-3-phosphate dehydrogenase) was found to be decreased, and the significance of these changes corresponded to the severity of clinical manifestations of CHD. The original drug Eltacin consisting of 3 nonessential amino acids: L-glutamic acid, glycine, and L-cystine (70 mg of each substance) was used. Clinical and cytochemical techniques were employed to evaluate therapeutic effectiveness from mitochondrial dehydrogenase activity in peripheral blood lymphocytes. The drug was found to positively affect the activity of mitochondrial enzymes. It was shown that for children with CHD the long-term Eltacin intake is necessary to have a lasting clinical effect.

Keywords: 
children
chronic heart failure
mitochondrial dehydrogenases
succinate dehydrogenase
glycerol-3-phosphate dehydrogenase
cytochemical assay
metabolic correction



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Basargina E.N. Sovremennye vzgljady na lechenie hronicheskoj serdech noj nedostatochnosti u detej // Ros. pediat. zhurn. – 2008; 1: 46–52.
  2. Mareev V.Ju., Ageev F.T., Arutjunov G.P. i dr. Natsional'nye rekomenda tsii VNOK i OSSN po diagnostike i lecheniju HSN (4-j peresm.) // Serdechnaja nedostatochnost'. 2013; 14 (81): 379–472.
  3. Bershova T.V., Bakanov M.I., Chibisov I.V. i dr. Organoprotektivnye i metabolicheskie effekty kompleksnoj terapii hronicheskoj serdechnoj nedostatochnosti u detej // Ros. med. zhurn. – 2008; 1: 26–9.
  4. Mutaf'jan O.A. Detskaja kardiologija / M.: GEOTAR-Media, 2009; 503 s.4.
  5. Skulachev V.P. Javlenija zaprogrammirovannoj smerti. Mitohondrii, kletki i organy: rol' aktivnyh form kisloroda // Sorosovskij obrazova-tel'nyj zhurnal. – 2001; 7 (6): 26–9.
  6. Hansen J., Young-Mi Go, Jones D. Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling // Ann. Rev. Pharmacol. Toxicol. – 2006; 46: 215–34.
  7. Circu M., Tak Yee Aw. Reactive oxygen species, cellular redox systems, and apoptosis // Free Radical Biology & Medicine. – 2010; 48: 749–62.
  8. Komissarova I.A., Kalinina E.V., Gudkova Ju.V. i dr. Farmatsevticheskaja . kompozitsija, indutsirujuschaja biosintez glutationa, aktivnost' glutation-transferazy i okazyvajuschaja antitoksicheskoe, radioprotektornoe i antigi-poksicheskoe dejstvie, i sposoby lechenija, profilaktiki i zaschity s ee ispol'zovaniem. Patent RF №2096034.- BI. 1997; 32 (2): 160–1
  9. Kalinina E.V., Komissarova I.A., Zaslavskaja R.M. i dr. Vlijanie meta bolitnogo preparata Eltatsin na oksidantnyj uroven' bol'nyh IBS pozhilo-go vozrasta // Klin. gerontol. – 2003; 9 (9): 9.
  10. Komissarova I., Zaslavskaia R. Eltacin – metabolic drag antioxidant 10. properties. Abstract of European Workshop on drug metabolism. Oct. 8. 2004.
  11. Maksimova L.N., Maksimov M.L., Nartsissov Ja.R. i dr. Rol' metabolit noj terapii v lechenii hronicheskoj serdechnoj nedostatochnosti // Rats. far-makoter. v kardiol. – 2013; 9 (5): 577–81.
  12. Maksimova L.N., Zaslavskaja R.M., Kalinina S.V. i dr. Klinicheskij opyt primenenija original'nogo metabolicheskogo preparata Eltatsin u bol'-nyh hronicheskoj serdechnoj nedostatochnost'ju // Effektivnaja farmakotera-pija. Kardiol. i angiol. – 2011; 5: 8–12.
  13. Petrichuk S.V. i soavt. Diagnosticheskie i prognosticheskie vozmozh nosti klinicheskoj tsitohimii. Metodicheskoe posobie dlja vrachej / M., 2005; 74 s.
  14. Pisareva I.V., Petrichuk S.V., Karaseva O.V. Snizhenie riska razvi tija posleoperatsionnyh oslozhnenij s primeneniem tsitoflavina pri appendikuljarnom peritonite u detej. Metodicheskoe posobie dlja vrachej / M., 2008; 28 s.
  15. Izmajlova T.D., Klimova S.V., Kuznetsova L.V. i dr. Aktivnost' mito-15. hondrial'nyh degidrogenaz limfotsitov perifericheskoj krovi u detej s bolezn'ju Krona // Ros. pediat. zhurn. – 2010; 6: 14–9.
  16. Nartsissov R.P., Shischenko V.M., Petrichuk S.V. i dr. Zdorov'e, bolezn' i lekarstvo (tsitohimicheskaja ekspertiza s pomosch'ju analizatora izobrazhe-nij) / M., 1999; 25 s.